Eli Lilly’s CEO promises not to raise insulin prices

Chiefs of Novo Nordisk, Sanofi, and Eli Lilly meet with the senate to discuss prices – but only the latter declares that new lower insulin prices are there to stay.
Photo: Leah Millis/Reuters/Ritzau Scanpix
Photo: Leah Millis/Reuters/Ritzau Scanpix
By Nacha Cattan and Ilena Peng, bloomberg

Eli Lilly & Co. won’t raise prices on any insulin products now on the market, Chief Executive Officer Dave Ricks told Senator Bernie Sanders at a hearing with big pharma executives as drugmakers come under increased scrutiny over soaring costs. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading